Aporte valor a la conversación. Céntrese en el tema a tratar y contribuya al debate con información de interés. Sea respetuoso. Recuerde que se puede rebatir un argumento de forma constructiva y diplomática. Cuide la redacción. Vigile la puntuación, las mayúsculas y las tildes.

Zacks Small-Cap Research scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 September 26, 2019 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 ARWR: Broad-Based Pipeline Progress. Three Pivotal Studies, Value-Inflection Opportunities In View. Moving PT to $36/Share Relative valuation metrics indicates fair value ARWR: Arrowhead Pharmaceuticals, Inc. - Full Company Report. Get the latest Full Company Report for Arrowhead Pharmaceuticals, Inc. from Zacks Investment Research By Grant Zeng, CFA NASDAQ:ARWR The Updated Data On December 6, Arrowhead (NASDAQ:ARWR) presented new data of ARC-520 from its Phase II clinical study in patients with chronic hepatitis B virus (HBV) infection at the 22nd biennial HEP DART meeting held in Kona, Hawaii, from Dec. 3-7. ARC-520 is the company’s first-generation RNAi-based clinical 1/1/2020 · Interactive Chart for Arrowhead Pharmaceuticals, Inc. (ARWR), analyze all the data with a huge range of indicators. Current Price Does Not Reflect Value . We maintain our Outperform rating on Arrowhead shares and reiterate our price target of $18.75 per share. Current market price does not reflect the intrinsic value of the Company. We believe recent pullback provides a buying opportunity. We cover ARWR with a $30/share price target. See link for free access to our updated report on the company. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. Based on analysts offering 12 month price targets for ARWR in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Sign in to your SmartPortfolio to see more analyst recommendations.

We cover ARWR with a $30/share price target. See link for free access to our updated report on the company. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.

ARWR: Arrowhead Pharmaceuticals, Inc. broker recommendations. Get the latest broker recommendations from Zacks Investment Research. Dig deep in into the key company metrics for Arrowhead Pharmaceuticals, Inc. from Zacks.com. Our Research. Your Success. Zacks Small-Cap Research scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 September 26, 2019 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 ARWR: Broad-Based Pipeline Progress. Three Pivotal Studies, Value-Inflection Opportunities In View. Moving PT to $36/Share Relative valuation metrics indicates fair value ARWR: Arrowhead Pharmaceuticals, Inc. - Full Company Report. Get the latest Full Company Report for Arrowhead Pharmaceuticals, Inc. from Zacks Investment Research

See the upcoming ex dividend date and dividend history for Arrowhead Pharmaceuticals, Inc. (ARWR). Stay alerted to dividend announcements for ARWR and all the

11/26/2019 · Arrowhead Pharmaceuticals (ARWR +16.5%) extends its recent run to multi-year highs as shares jump in response to its full-year financial results, with revenues soaring 946% Y/Y to $169M; shares have gained ~430% YTD. 1/1/2020 · Get the latest Arrowhead Pharmaceuticals, Inc. (ARWR) stock news and headlines to help you in your trading and investing decisions.

JNJ1, per ARWR, is being developed against an undisclosed liver-expressed target. As a reminder, ARWR is responsible for preclinical development (fully funded by Janssen) up to filing of an IND, at which point Jansen has the option to take an exclusivity license and continue development.

Zacks Investment Research Page 2 scr.zacks.com WHATS NEW Janssen Collaboration Announced on October 4th and closed at the end of the same month, ARWR received $250M upfront upon closing and is eligible for another $3.5B in potential additional milestones and for royalties on eventual commercial sales. 6/20/2002 · Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.04. The reported EPS for the same quarter last year was $0.13. Aporte valor a la conversación. Céntrese en el tema a tratar y contribuya al debate con información de interés. Sea respetuoso. Recuerde que se puede rebatir un argumento de forma constructiva y diplomática. Cuide la redacción. Vigile la puntuación, las mayúsculas y las tildes. Arrowhead Pharmaceuticals, Inc. Message board - Online Community of active, educated investors researching and discussing Arrowhead Pharmaceuticals, Inc. Stocks. Zacks Investment Research Page 3 scr.zacks.com AAT sustained reduction of mutant Z-AAT protein1 JNJ-3989 EASL Presentation Also at EASL ILC ARWR presented interim results of JNJ-3989 (ARO-HBV) among 40 patients at 24+ weeks follow-up in their ongoing AROHBV1001 study. Zacks Projected EPS Growth Rate - Next 5 Years % N/A Zacks Small-Cap Research scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 January 8, 2019 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 ARWR: ANG3 Ph1 in Dyslipidemia Commences Relative valuation metrics indicates a fair value at $30/share.

View Arrowhead Pharmaceuticals, Inc. ARWR investment & stock information. Get the latest Arrowhead Pharmaceuticals, Inc. ARWR detailed stock quotes, stock 

Arrowhead Pharmaceuticals Corp. company facts, information and stock details by MarketWatch. View arwr business summary and other industry information. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to r ec eive o ur articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR and to view our disclaimer. Find the latest Arrowhead Pharmaceuticals, Inc. (ARWR) stock quote, history, news and other vital information to help you with your stock trading and investing. Stock quote for Arrowhead Pharmaceuticals, Inc. Common Stock Common Stock (ARWR) with real-time last sale and extended hours stock prices, company news, charts, and

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them.